Cardio-oncology Related to Heart Failure, An Issue of Heart Failure Clinics, 1st Edition
Authors :
Daniel J. Lenihan & Douglas B. Sawyer
Date of Publication: 09/2011
As the number of effective anti-neoplastic agents has grown, there has been a concomitant increase in side effects. Cardiotoxicity, and specifically LV dysfunction, remains the limiting factor for many such agents, and is the focus of growing r ...view more
As the number of effective anti-neoplastic agents has grown, there has been a concomitant increase in side effects. Cardiotoxicity, and specifically LV dysfunction, remains the limiting factor for many such agents, and is the focus of growing research and clinical emphasis. This issue summarizes for the heart failure specialist the possible ways that chemotherapeutic agents might cause cardiotoxicity as well as the methods for detecting, treating and preventing cardiotoxicity.
As the number of effective anti-neoplastic agents has grown, there has been a concomitant increase in side effects. Cardiotoxicity, and specifically LV dysfunction, remains the limiting factor for many such agents, and is the focus of growing research and clinical emphasis. This issue summarizes for the heart failure specialist the possible ways that chemotherapeutic agents might cause cardiotoxicity as well as the methods for detecting, treating and preventing cardiotoxicity.
Author Information
By Daniel J. Lenihan, MD, FACC, Professor of Medicine, Director, Cardio-Oncology Center of Excellence, Advanced Heart Failure, Clinical Research, Cardiovascular Division, Washington University in St. Louis, St. Louis Missouri and Douglas B. Sawyer, M.D., Ph.D., FACC, Maine Medical Center Department of Cardiac Services Portland, ME, USA
https://www.mea.elsevierhealth.com/cardio-oncology-related-to-heart-failure-an-issue-of-heart-failure-clinics-9781455711017.html117278Cardio-oncology Related to Heart Failure, An Issue of Heart Failure Clinicshttps://www.mea.elsevierhealth.com/media/catalog/product/9/7/9781455711017_1.jpg74.2498.99USDInStock/Medicine and Surgery/Cardiology/Books/Clinics Review Articles99275255039561283813733745145120As the number of effective anti-neoplastic agents has grown, there has been a concomitant increase in side effects. Cardiotoxicity, and specifically LV dysfunction, remains the limiting factor for many such agents, and is the focus of growing research and clinical emphasis. This issue summarizes for the heart failure specialist the possible ways that chemotherapeutic agents might cause cardiotoxicity as well as the methods for detecting, treating and preventing cardiotoxicity. As the number of effective anti-neoplastic agents has grown, there has been a concomitant increase in side effects. Cardiotoxicity, and specifically LV dysfunction, remains the limiting factor for many such agents, and is the focus of growing research and clinical emphasis. This issue summarizes for the heart failure specialist the possible ways that chemotherapeutic agents might cause cardiotoxicity as well as the methods for detecting, treating and preventing cardiotoxicity.USD00add-to-cart97814557110172011 and earlierProfessionalBy Daniel J. Lenihan, MD, FACC and Douglas B. Sawyer, M.D., Ph.D., FACC20111Book178w x 254h (7.00" x 10.00")Saunders16815 Sep 2011PRINT ON DEMAND - DELIVERY CAN TAKE UP TO 10 DAYSBy <STRONG>Daniel J. Lenihan</STRONG>, MD, FACC, Professor of Medicine, Director, Cardio-Oncology Center of Excellence, Advanced Heart Failure, Clinical Research, Cardiovascular Division, Washington University in St. Louis, St. Louis Missouri and <STRONG>Douglas B. Sawyer</STRONG>, M.D., Ph.D., FACC, Maine Medical Center Department of Cardiac Services Portland, ME, USAClinicsThe Clinics: Internal MedicineNoNoNoNoPlease SelectPlease SelectPlease Select
